Pfizer (PFE) Leases (2019 - 2025)

Pfizer (PFE) has 7 years of Leases data on file, last reported at $2.2 billion in Q4 2025.

• Quarterly Leases fell 3.32% year-over-year to $2.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 billion (down 3.32% YoY) and the FY2025 annual result came in at $2.2 billion, down 3.32% from the prior year.
• Leases eased to $2.2 billion in Q4 2025 per PFE's latest filing, from $2.3 billion in the prior quarter.
• Across five years, Leases topped out at $3.0 billion in Q4 2022 and bottomed at $2.2 billion in Q4 2025.
• The 5-year median for Leases is $2.8 billion (2021), against an average of $2.7 billion.
• The widest annual swing landed in 2021, when Leases soared 104.83%; it then slipped 21.72% in 2024.
• Tracing PFE's Leases over 5 years: stood at $2.8 billion in 2021, then gained by 5.74% to $3.0 billion in 2022, then dropped by 2.6% to $2.9 billion in 2023, then fell by 21.72% to $2.3 billion in 2024, then fell by 3.32% to $2.2 billion in 2025.
• Per Business Quant, the three latest PFE Leases figures stand at $2.2 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.9 billion (Q4 2023).

Peer Comparison